Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …

Objectives: Tumours remain a serious threat to human life. Following rapid progress in
oncology research, tyrosine kinase inhibitors have been used to treat multiple tumour types …

The efficacy of apatinib has been confirmed in the treatment of solid tumors, including non-
small-cell lung cancer (NSCLC). However, the direct functional mechanisms of tumor …

The most common driver gene mutation in patients with non‐small‐cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of …

Simple Summary The presence of an EGFR activating mutation in tumors of non-small-cell
lung cancer patients enables effective targeted therapy towards EGFR. Studies that describe …

Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …

Members of the EGFR family of tyrosine kinase receptors are major regulators of cellular
proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is …

Purpose: In early-stage, EGFR mutation–positive (EGFR-M+) non–small cell lung cancer
(NSCLC), surgery remains the primary treatment, without personalized adjuvant treatments …

Lung cancer is one of the most prevalent tumors with rapid progression and poor prognosis,
which badly affects human physical and mental health. Although traditional anti-cancer …

Lung cancer, as a malignant tumor with both high incidence and mortality in China, is one of
the major causes of death in our population and one of the major public health problems in …